Biomedical research at Oslo University Hospital

Oslo University Hospital is a merger of three former university hospitals in Oslo. Biomedical research is one of the hospital's core activities. Research at the hospital is closely interlinked with research undertaken at the University of Oslo. More than 50% of all biomedical research in Norway is published by researchers affiliated with the hospital. Research undertaken cover both basic research, translational research, and clinical research.

Oslo University Hospital has a central role in developing and supporting biomedical research within the South-Eastern Regional Health Authority. The hospital also pursues international research collaborations.

Click here to see hierarchical division and subunit overview

Summary of publications:

Publications (original articles or review articles) published in 2019 from OUS - Section for head and neck oncology

13 publications found

Bogsrud TV, Londalen A, Brandal P, Leske H, Panagopoulos I, Borghammer P, Bach-Gansmo T (2019)
18F-Fluciclovine PET/CT in Suspected Residual or Recurrent High-Grade Glioma
Clin Nucl Med, 44 (8), 605-611
DOI 10.1097/RLU.0000000000002641, PubMed 31274605

Brandstorp-Boesen J, Zätterström U, Evensen JF, Boysen M (2019)
Value of patient-reported symptoms in the follow up of patients potentially cured of laryngeal carcinoma
J Laryngol Otol, 133 (6), 508-514
DOI 10.1017/S0022215119000677, PubMed 31006407

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes BGM, Mesía R, Ngamphaiboon N, Rordorf T, Wan Ishak WZ, Hong RL, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng JD, Jin F, Rischin D, KEYNOTE-048 Investigators (2019)
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study
Lancet, 394 (10212), 1915-1928
DOI 10.1016/S0140-6736(19)32591-7, PubMed 31679945

Latysheva A, Emblem KE, Brandal P, Vik-Mo EO, Pahnke J, Røysland K, Hald JK, Server A (2019)
Dynamic susceptibility contrast and diffusion MR imaging identify oligodendroglioma as defined by the 2016 WHO classification for brain tumors: histogram analysis approach
Neuroradiology, 61 (5), 545-555
DOI 10.1007/s00234-019-02173-5, PubMed 30712139

Lundar T, Due-Tønnessen BJ, Frič R, Brandal P, Stensvold E, Due-Tønnessen P (2019)
Adult outcome after neurosurgical treatment of brain tumours in the first year of life: long-term follow-up of a single consecutive institutional series of 34 patients
Acta Neurochir (Wien), 161 (9), 1793-1798
DOI 10.1007/s00701-019-04014-z, PubMed 31309304

Moan JM, Amdal CD, Malinen E, Svestad JG, Bogsrud TV, Dale E (2019)
The prognostic role of 18F-fluorodeoxyglucose PET in head and neck cancer depends on HPV status
Radiother Oncol, 140, 54-61
DOI 10.1016/j.radonc.2019.05.019, PubMed 31177043

Röhrl K, Guren MG, Astrup GL, Småstuen MC, Rustøen T (2019)
High symptom burden is associated with impaired quality of life in colorectal cancer patients during chemotherapy:A prospective longitudinal study
Eur J Oncol Nurs, 44, 101679
DOI 10.1016/j.ejon.2019.101679, PubMed 31751848

Singer S, Amdal CD, Hammerlid E, Tomaszewska IM, Castro Silva J, Mehanna H, Santos M, Inhestern J, Brannan C, Yarom N, Fullerton A, Pinto M, Arraras JI, Kiyota N, Bonomo P, Sherman AC, Baumann I, Galalae R, Fernandez Gonzalez L, Nicolatou-Galitis O, Abdel-Hafeez Z, Raber-Durlacher J, Schmalz C, Zotti P, Boehm A et al. (2019)
International validation of the revised European Organisation for Research and Treatment of Cancer Head and Neck Cancer Module, the EORTC QLQ-HN43: Phase IV
Head Neck, 41 (6), 1725-1737
DOI 10.1002/hed.25609, PubMed 30636188

Stensvold E, Myklebust TÅ, Cappelen J, Due-Tønnessen BJ, Due-Tønnessen P, Kepka A, Johannesen TB, Krossnes B, Lundar T, Maric S, Miletic H, Moholdt V, Myrmel KS, Nordberg T, Rydland J, Stokland T, Solem K, Solheim O, Torsvik I, Wikran GC, Zeller B, Wesenberg F, Bechensteen AG, Brandal P (2019)
Children treated for medulloblastoma and supratentorial primitive neuroectodermal tumor in Norway from 1974 through 2013: Unexplainable regional differences in survival
Pediatr Blood Cancer, 66 (10), e27910
DOI 10.1002/pbc.27910, PubMed 31264356

Stokkevåg CH, Indelicato DJ, Herfarth K, Magelssen H, Evensen ME, Ugland M, Nordberg T, Nystad TA, Hægeland C, Alsaker MD, Ulven K, Dale JE, Engeseth GM, Boer CG, Toussaint L, Kornerup JS, Pettersen HES, Brydøy M, Brandal P, Muren LP (2019)
Normal tissue complication probability models in plan evaluation of children with brain tumors referred to proton therapy
Acta Oncol, 58 (10), 1416-1422
DOI 10.1080/0284186X.2019.1643496, PubMed 31364899

Sunde B, Johnsen G, Jacobsen AB, Glenjen NI, Friesland S, Lindblad M, Rouvelas I, Wang N, Lundell L, Lagergren P, Nilsson M (2019)
Effects of neoadjuvant chemoradiotherapy vs chemotherapy alone on the relief of dysphagia in esophageal cancer patients: secondary endpoint analysis in a randomized trial
Dis Esophagus, 32 (2)
DOI 10.1093/dote/doy069, PubMed 30084992

Sunde B, Klevebro F, Johar A, Johnsen G, Jacobsen AB, Glenjen NI, Friesland S, Lindblad M, Ajengui A, Lundell L, Lagergren P, Nilsson M (2019)
Health-related quality of life in a randomized trial of neoadjuvant chemotherapy or chemoradiotherapy plus surgery in patients with oesophageal cancer (NeoRes trial)
Br J Surg, 106 (11), 1452-1463
DOI 10.1002/bjs.11246, PubMed 31436322

von Döbeln GA, Klevebro F, Jacobsen AB, Johannessen HO, Nielsen NH, Johnsen G, Hatlevoll I, Glenjen NI, Friesland S, Lundell L, Yu J, Nilsson M (2019)
Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the esophagus or gastroesophageal junction: long-term results of a randomized clinical trial
Dis Esophagus, 32 (2)
DOI 10.1093/dote/doy078, PubMed 30137281

 
Page visits: 352646